CD8B and neoplasm: Interestingly, a slow-down in tumour growth (Figure 2B, top right panel) and improved survival (Figure 2B, bottom right panel) was apparent when ‘Anti-CD8β + Anti-Gr-1’ was compared to CD8β+-depletion alone, and two out of eight animals could reject established SCC tumours.